Match Document Document Title
6491924 Chlamydia pneumoniae antigenic polypeptide  
Chlamydia pneumoniae antigenic polypeptides, which comprise polypeptide A containing a sequence of at least 5 consecutive amino acids in the polypeptide of SEQ ID NO: 1; DNAs encoding the...
6486132 Immunomodulator, immunomodulator food and immunomodulator feed  
To provide an immunomodulator in which DNA can be administered orally or percutaneously, not through injection, or can be taken daily like a food, or an immunomodulator food or feed. DNA derived...
6479056 Live vaccine constituting minor risk for humans  
A salmonella live vaccine produced from at least one attenuated immunologic live vaccine strain, characterized in that the vaccine strain has an envelope marker which results in an increased...
6475492 Peptides and assays for the diagnosis of lyme disease  
A peptide consisting of an invariable 26-amino-acid-long region, named IR 6 , which is antigenically conversed among strains and species of the B. burgdorferi sensu lato complex, and...
6476201 Methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines  
A continuous method for preparing proteosome-amphiphilic determinant vaccines for parenteral or mucosal administration using diafiltration or ultrafiltration technology. The amphiphilic...
6472183 Immunity against Actinobacillus pleuropneumoniae's RTX toxins APX  
Disclosed herein is a modified microorganism which produces an RTX toxin, wherein said RTX toxin is partially or fully inactivated. Also disclosed is a modified microorganism wherein an RTX toxin...
6471966 Type 1 and type p fimbriae-adhesins isolated from novel e. coli strains, process for their preparation and uses thereof  
Fimbriae adhesins have a molecular weight of 2×10 5 and 2×10 7 Da, and are comprised of 90-95% protein and 1-3% sugar. Type 1 fimbriae include five different protein fractions of 14-20 kDa,...
6471967 Recombinant intracellular pathogen vaccines and methods for use  
Vaccines and immunotherapeutics for preventing intracellular pathogen diseases in mammals are provided that consist of recombinant attenuated intracellular pathogens that have been transformed to...
6464979 Chlamydial vaccines and methods of preparation thereof  
Immunogenic compositions including vaccines are described that comprise an outer membrane antigen extract of a strain of Chlamydia and are effective in protection against disease caused by...
6464985 Compositions and methods using the borreliacidal epitope(s) of Borrelia burgdorferi outer surface protein C (OspC) for the diagnosis and prevention of lyme disease  
An OspC Dra fragment fusion peptide isolated from Borrelia burgdorferi is described herein for the prevention, treatment and early diagnosis of Lyme disease in humans and other animals. This...
6461614 Fibronectin binding proteins  
The invention provides Fibronectin Binding Protein polypeptides and DNA (RNA) encoding Fibronectin Binding Protein polypeptides and methods for producing such polypeptides by recombinant...
6458367 Method for detecting the presence of a mycobacterium species and a kit and antibodies for use therein  
The invention relates to a diagnostic test for the detection and identification of Mycobacterium species in biological specimens of human and animal origin. The test is based on the immunological...
6458368 Attenuated microorganism strains expressing HPV proteins  
Attenuated strain of a prokaryotic microorganism, being an attenuated strain of Salmonella suitable for use in a live vaccine for administration to a human or animal, in which the microorganism is...
6455052 Enteric coating, comprising alginic acid, for an oral preparation  
A composition for forming an enteric coating on a tablet, capsule or pellet for oral ingestion includes a liquid mixture of alginic acid particles dispersed in an aqueous solution of a binding...
6451338 Liposomes containing particulate materials  
A method is provided for the formation of liposomes of 0.1 μm to 50 μm in diameter having unilamella or multilamella structure and containing water insoluble or undissolved particulate materials...
6448230 Testis expressed polypeptide  
The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells,...
6444448 Production of β-glucan-mannan preparations by autolysis of cells under certain pH, temperature and time conditions  
There is provided a method of production of an immunostimulatory β-glucan-mannan preparation, comprising the step of autolysis of cells of a microorganism at a pH of 5 to 6 and a temperature of 35...
6440426 Antigen-containing formulation and methods of use thereof  
An antigen-containing formulation is provided, comprising: (a) an antigen; (b) a TH1-inducing adjuvants; and (c) a sparingly soluble amino acid or a derivative thereof. The adjuvants may be, for...
6440423 Mutant enterotoxin effective as a non-toxic oral adjuvant  
Methods and compositions are provided herein for the se of a novel mutant form of E. coli heat-labile enterotoxin which has lost its toxicity but has retained its immunologic activity. This...
6436407 Mutant enterotoxin effective as a non-toxic adjuvant  
Methods and compositions are provided herein for the use of a novel mutant form of E. coli heat-labile enterotoxin which has lost its toxicity but has retained its immunologic activity. This...
6423320 Inhibitor of immunoglobulin E antibody production  
A polysaccharide and fragments thereof derived from Klebsiella oxytoca or Klebsiella pneumonia inhibit the IgE antibody production and response and, therefore, are useful in the prophylaxis...
6416976 TrpS  
The invention provides trpS polypeptides and DNA (RNA) encoding trpS polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing trpS...
6413523 Pharmaceutical composition of escherichia coli heat-labile enterotoxin adjuvant and methods of use  
Novel immunoregulatory utilities of Escherichi coli heat-labile enterotoxin (LT) are disclosed. This enterotoxin can be used in combination with an unrelated antigen to achieve a higher immune...
6410688 Def1  
The invention provides Def1 polypeptides and DNA (RNA) encoding Def1 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing Def1...
6406703 Treatment of H. pylori associated gastroduodenal disease  
The application discloses a method for the treatment of Heliobacter infection in a mammalian host, which comprises administration to said infected host of an immunologically effective amount of one...
6406887 Compositions for diagnosing Rochalimaea henselae and Rochalmaea quintana infection  
Fusion protein compositions containing the sequence of a 17 kilodalton antigenic polypeptide of Rochalimaea (SEQ ID NO:12) are disclosed for diagnosis of cat scratch disease and bacillary...
6403093 Methods to detect granulocytic ehrlichiosis  
An isolated nucleic acid molecule associated with human granulocytic ehrlichiosis is provided. Also provided are methods to detect the presence of the nucleic acid molecule, and antibodies specific...
6403100 Method of attenuating pathogenic mycobacteria and strains of mycobacteria so attenuated  
This invention provides for novel attenuated strains of Mycobacterium tuberculosis and M. bovis. Attenuation is achieved by eliminating or by downregulating the expression of the α-crystallin...
6403094 Clostridium perfringens vaccines  
The present invention provides proteins for use in vaccines which are capable of inducing protective antibodies directed against C. perfringens epsilon toxin when administered to animals or man...
6399070 Methods and compositions for eliciting an immune response with hsp90-peptide complexes  
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases....
6399069 Prevention of infectious diseases with hsp70-peptide complexes  
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases....
6395282 Immunogenic conjugates of Gram-negative bacterial autoinducer molecules  
The present invention relates to an immunogenic conjugate comprising a carrier molecule coupled to an autoinducer of a Gram negative bacteria. The immunogenic conjugate, when combined with a...
6391306 Treatment of infectious diseases with hsp90-peptide complexes  
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases....
6391570 Methods and compositions for the detection of bacterial endotoxins  
The invention provides methods and compositions for the detection and/or quantification of bacterial endotoxins. In particular, provided herein is an inexpensive and reproducible method for...
6391313 Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis  
A multi-valent immunogenic composition confers protection on an immunized host against infection caused by both Haemophilus influenzae and Moraxella catarrhalis . Such composition comprises at...
6387372 Polypeptides from mycrobacterium paratuberculosis  
The invention relates to a polypeptide containing in its polypeptidic chain: the amino acid sequence of 101 amino acids of FIG. 8, or a fragment of this sequence, this fragment being such that it...
6387665 Method of making a vaccine for anthrax  
A method of making a vaccine for anthracis that inolves a bacterial expression system and production and use of protective antigen (PA) against Bacillus anthracis . The PA immunogen is useful in a...
6383491 Prevention of infectious diseases with hsp90-peptide complexes  
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases....
6383492 Treatment of infectious diseases with gp96-peptide complexes  
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases....
6383498 Compositions for vaccines  
Neuraminidase and galactose oxidase together are a vaccine adjuvant.
6383494 Methods and composition for eliciting an immune response with gp96-peptide complexes  
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases....
6379676 Enhancing immune response in animals  
A method for improving the immune response of an animal to a vaccine, comprising: feeding an animal a diet of contamination-resistant feed, and treating said animal with an anti-viral or...
6379677 Streptococcus iniae vaccine  
Safe and effective mono and polyvalent vaccines against Streptococcus iniae may be prepared from formalin-killed cells and concentrated extracellular products of Streptococcus iniae which include...
6379672 Prevention of infectious diseases with gp96-peptide complexes  
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases....
6375953 Treatment of infectious diseases with HSP70-peptide complexes  
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases....
6375954 Size-variable strain-specific protective antigen for potomac horse fever  
An isolated and purified antigen which is expressed by a wild-type E. risticii strain and is specific to the strain. The present invention also relates to nucleic acid constructs which encode the...
6372225 Tetanus toxin functional fragment antigen and tetanus vaccine  
Disclosed is a tetanus toxin functional fragment antigen (FFA), comprising at least one fragment which is substantially the same as that obtained by a process comprising the steps of splitting at...
6372222 Antigenic group B Streptococcus type II and type III polysaccharide fragments having a 2, 5-anhydro-D-mannose terminal structure and conjugate vaccine thereof  
The process for depolymerizing Group B Types II and III Streptococcal Polysaccharide is disclosed which results in polysaccharide fragments having a reducing end suitable for conjugating to...
6368605 Method for treating cancer with a neurotoxin to improve patient function  
A method for reducing a catecholamine secretion from a cholinergically innervated, functional chromaffin body, such as a paraganglioma or hyperplasic adrenal medulla, by direct, local...
6368603 Lyme combination compositions and uses  
Disclosed and claimed are compositions containing a Borrelia burgdorferi antigen, and methods for making and using them. The antigen can be OspA. The compositions can contain at least one...